Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alyson Harty
Observed name:
A. Harty
Institution:
Icahn School of Medicine at Mount Sinai
Observed institutions:
Mount Sinai Hospital,
Mount Sinai Hospital,
Mount Sinai Hospital,
Mount Sinai Hospital,
Janssen Scientific Affairs (United States),
Icahn School of Medicine at Mount Sinai
show all 6
ORCID:
0000-0002-8979-4905
Observed ORCID:
0000-0002-8979-4905
OpenAlex ID:
A5012438003
Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus
2016
·
Sweta Chekuri
, Jillian Nickerson
, et al.
·
PLoS ONE
·
83
PDF
Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV
2016
·
David Del Bello
, Agnes Cha
, et al.
·
Clinical Infectious Diseases
·
25
PDF
Improving Advance Care Planning in Outpatients With Decompensated Cirrhosis: A Pilot Study
2019
·
Arpan Patel
, Nina Kogekar
, et al.
·
Journal of Pain and Symptom Management
·
18
PDF
Hepatitis C cure improved patient‐reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center
2019
·
Julie C. Sung
, Ciara Bosh
, et al.
·
Journal of Viral Hepatitis
·
14
A Digital Case‐Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure
2021
·
Brooke Wyatt
, Ponni V. Perumalswami
, et al.
·
Hepatology
·
12
PDF
Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results
2017
·
Kian Bichoupan
, Neeta Tandon
, et al.
·
World Journal of Virology
·
9
PDF
High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV ‐infected patients treated with sofosbuvir‐containing regimens
2016
·
P. V. Perumalswami
, N. Patel
, et al.
·
Journal of Viral Hepatitis
·
6
Identifying Environmental Factors Associated with Significant Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis
2025
·
Alejandra Paredes-Marin
, Julia Napoli
, et al.
·
Digestive Diseases and Sciences
·
5
Outcomes of a 3-Year Quality Improvement Study to Improve Advance Care Planning in Patients With Decompensated Cirrhosis
2023
·
Arpan Patel
, Chip A. Bowman
, et al.
·
The American Journal of Gastroenterology
·
5
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus
2016
·
Neal Patel
, Kian Bichoupan
, et al.
·
World Journal of Gastroenterology
·
5
PDF
Real-world Comparison of Steatosis-Associated Fibrosis Estimator and Fibrosis-4 Scores for Assessing Metabolic Dysfunction-associated Steatotic Liver Disease-related Fibrosis in a Highly Diverse Urban Metabolic Dysfunction-associated Steatotic Liver Disease Population
2025
·
Xiaotao Zhang
, Vikram Sivakumar
, et al.
·
Clinical Gastroenterology and Hepatology
·
4
Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection Treatment.
2014
·
Bevin Hearn
, David Delbello
, et al.
·
Europe PMC (PubMed Central)
·
2
FRI-246-Elimination of HCV in a Large Urban Health System in the United States: A Big-data Approach
2019
·
Ponni Perumalswami
, Brooke Wyatt
, et al.
·
Journal of Hepatology
·
1
P0881 : Real world effectiveness and cost of simeprevir- and/or sofosbuvir-based HCV treatments: $175,000 per SVR12
2015
·
K. Bichoupan
, N. Tandon
, et al.
·
Journal of Hepatology
·
1
Case Series: Change in Genotype in Patients with Chronic Hepatitis C
2016
·
Tamara Brodsky
, Douglas Dieterich
, et al.
·
The American Journal of Gastroenterology
Show more works
View as search
Works count:
15
Citation count:
190
H-index:
6
I10-index:
5
Year
Topic
Type